【摘要】 目的　探讨非诺贝特和普伐他汀联合治疗混合性高脂血症的远期疗效及安全性。方法　 38例确诊混合性高脂血症患者 ,联合应用非诺贝特和普伐他汀 (微粒化力平脂 2 0 0mg/d ,普拉固 10mg/d) ,进行为期 2年的治疗 ,治疗前后均测定空腹血脂、肌酸磷酸激酶 (CPK)、肝肾功能以及尿酸等指标 ,观察对患者的远期疗效和安全性。结果　联合治疗患者总胆固醇 (TC)显著下降 2 5 %± 6 % ,甘油三酯 (TG)下降 40 %± 5 % ,低密度脂蛋白 (LDL C)下降 2 7%± 3% ,高密度脂蛋白 (HDL C)上升 2 1%± 6 % ;谷丙转氨酶 (ALT)活性上升(3± 2 )U·L-1(无显著意义 ) ,CPK活性下降 (4± 8)U·L-1(无显著意义 ) ,无一例出现严重并发症。结论　非诺贝特联合普伐他汀治疗肝肾功能正常的混合性高脂血症患者是有效而且安全的。更多还原

【Abstract】 Objective To investigate the long-term efficacy and safety of combination therapy with fenofibrate and pravastatin in the treatment of combined hyperlipidemia. Methods 38 patients with combined hyperlipidemia were treated with combination of fenofibrate together with pravastatin (micronised Lipanthyl 200 mg plus pravastatin 10 mg once daily). The combination therapy has been conducted for 2 years. Fasting blood lipid, creatinine phosphokinase (CPK), hepatic and renal function, uric acid were obtained before and after combination therapy. The long-term efficacy and safety of combination therapy for patients was assessed. Results Patients receiving combination therapy had a mean total cholesterol (TC) that was significantly decreased by 25%±6%, triglycerides (TG) by 40%±5%, and low-density lipoprotein cholesterol (LDL-C) by 27%±3%, and mean high-density lipoprotein cholesterol (HDL-C) that was significantly increased by 21%±6%. During combination therapy, alanine aminotransferase (ALT) increased by (3±2)U/L (not significant), CPK decreased by (4±8) U/L (not significant). No severe complications were observed. Conclusion Combination therapy with fenofibrate and low-dose pravastatin is generally effective and safe for the treatment of combined hyperlipidemia in patients with normal hepatic and renal function.更多还原